RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All FDA (CBER) updates
FDA (CBER)
GUIDANCE DRAFT
Potency Assessment of Active Immunotherapy Products
Published: 8/19/2026Detected: 9/4/2026

Summary preview

Clarifies FDA expectations for potency assessment strategies for active immunotherapy products, which may influence how sponsors design potency assays and justify assay suitability across product lifecycle changes.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
immunology
infectious_disease
oncology
rare_diseases
manufacturing
quality
clinical
safety
labeling
#active immunotherapy
#potency assay

Official Source Document
Source Verified

Access the original document directly from FDA CBER.

View Official Document

More from FDA (CBER)

  • Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method9/16/2026
  • Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products: Guidance for Industry8/19/2026
  • Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry6/29/2026
  • Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing6/2/2026
  • Submitting Continuous Glucose Monitoring Data in Clinical Trials5/6/2026

Get FDA (CBER) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
#CMC
#bioassay
#acceptance criteria
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.